Sinopharm mulls $1B buyout of China-based DNA synthesis company — report
After spending the last couple of years laser-focused on its inactivated Covid-19 vaccine, Sinopharm is reportedly in the market to expand its DNA synthesis capabilities — and it may be willing to pay a pretty penny.
Sinopharm is considering a $1 billion-plus deal to snap up China-based BBI Life Sciences, unnamed sources told Bloomberg. The company has reportedly been in talks with the Wang family, who founded BBI back in 2013.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 147,200+ biopharma pros reading Endpoints daily — and it's free.